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EDITORIAL
Are Trials of Intravascular Infusions of
Autologous Mesenchymal Stem Cells in
Patients with Multiple System Atrophy
Currently Justified, and Are
They Effective?
Multiple system atrophy (MSA) is a rare, sporadic,fatal multisystem progressive disorder characterized
by autonomic failure, orthostatic hypotension, neuro-
genic bladder/erectile dysfunction, cerebellar ataxia, corti-
cospinal dysfunction, and parkinsonism that may be
poorly L-dopa responsive.1 MSA in Asia has a predomi-
nance of cerebellar ataxia (MSA-C), whereas the United
States and Europe have a predominance of parkinsonism
(MSA-P). Mean survival from diagnosis to death is 7 to
10 years.2,3 Currently, there are no treatments that halt
or reverse disease progression. Neuropathologically, MSA
is characterized by glial cytoplasmic inclusions of abnor-
mally aggregated a-synuclein with loss of nearby neu-
rons.4 Disease progression is thought to be causally
linked to accumulation and aggregation of a-synuclein,
and accordingly considerable effort has gone into devis-
ing strategies to combat these events.5 Recent work with
transgenic models suggests that a redistribution of neuro-
nal to oligodendroglial a-synuclein may take place in the
pathophysiology of MSA, but the precise mechanism by
which aggregation leads to neuronal loss is unproven.6
Recent evidence suggests a resulting deficiency of growth
factors, especially brain-derived neurotrophic factor and
glial cell-derived neurotrophic factor, which might
respond to infusion of mesenchymal stem cells (MSCs).7
Against this background, the open-label study by
Lee et al8 reporting that MSC infusion halts the progres-
sion of MSA sparked interest in the potential value of
MSCs in the treatment of MSA. A commentary on the
publication criticized the limited scientific basis for the
study and the lack of blinding.9 The current publica-
tion10 has greater scientific credibility. The study was
performed at a single center and comprises a double-
blind, placebo-controlled treatment trial on 33 subjects
with MSA-C (17 placebo and 16 MSCs). MSCs or
placebo was infused intra-arterially sequentially into the
internal carotid arteries and dominant vertebral artery fol-
lowed by subsequent infusions (at 1, 2, and 3 months)
intravenously. The primary endpoint consisted of a mixed
model approach to the total unified MSA rating score
(UMSARS). This scoring system rates the symptoms and
functional status of relevant activities of daily living
(UMSARS I) and a motor examination (UMSARS II).
Secondary endpoints included UMSARS II, cerebral glu-
cose metabolism, and estimated gray matter density. The
results included improvement in both UMSARS II and
UMSARS total, with the secondary endpoints all trending
in the appropriate direction. This potentially important
study stimulates a number of questions. Does the study
demonstrate that we have a treatment for MSA? Is the
treatment safe? What is the mechanism of action? How do
the MSCs breach the blood–brain barrier (BBB)?
One key issue in MSC treatment of MSA is develop-
ing access to target tissue across the BBB. This is a signifi-
cant barrier to the delivery of stem cells, although it
appears to be less intact in MSA than in normal subjects.
In a study that evaluated the integrity of the BBB with 2
clinical methods, the barrier was less tight in MSA than in
normal subjects,11 and the impairment correlated with the
severity of disease (UMSARS score). Nevertheless, the
remaining barrier continues to constitute a major hurdle to
MSC access. Because growth factors also do not generally
cross the BBB, peripheral stem cell delivery may not reach
target neurons in the relevant areas of the brain. Intrave-
nous infusion results in poor delivery to target tissue
because of entrapment and loss of MSCs, especially in lungs,
but also in liver and spleen,12,13 resulting in minimal engraft-
ment of stem cells in the brain. In contrast, intra-arterial
administration of stem cells significantly improves engraft-
ment into target brain tissue.14 The safety of intra-arterial
injection is controversial, and both development of micro-
strokes and increased mortality have been reported.15
The study by Lee et al is clearly a potentially im-
portant step forward in the treatment of a fatal disease.
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The investigators met their primary endpoint coupled
with some positive secondary endpoints, including
improvement in 18F-fluorodeoxyglucose positron emission
tomography glucose metabolism, cortical density, and cog-
nitive scores. Despite the positive findings, this study
leaves unresolved a number of issues on efficacy. First, this
is a single-center study, whereas a study involving multiple
centers might have provided more robust data. Second,
the study was performed on a relatively small number of
subjects. Third, the study was confined to MSA-C,
whereas the majority of MSA subjects in the USA and
Europe have MSA-P. Fourth, authors found significant
improvement in total UMSARS and UMSARS II (motor
examination), but not in the quality of life scale
(UMSARS I), meaning that over a year, the level of func-
tioning was insufficient to improve the patients’ quality of
life. Fifth, the results over time suggest only a transient
improvement, with the treatment losing much of its bene-
fit within months after the treatment.
There are significant concerns regarding the safety of
intra-arterial infusions. A significant percentage (29% of
MSC-treated and 35% of placebo-treated) patients devel-
oped ischemic lesions on magnetic resonance imaging,
including 1 subject who had transient neurologic deficits.
The authors seem rather cavalier in dismissing this prob-
lem as simply due to the intra-arterial approach. The
mechanism of benefit is also uncertain. If MSCs provide
growth or other factors that delay entry of neurons into the
apoptotic pathway, and the benefit is transient, then
repeated infusions are likely necessary. The approach car-
ries an unacceptable risk. Whither the path forward?
Clearly this current approach is not a cure for MSA, but
may have the potential of delaying progression. In compar-
ison to the previous unblinded study of MSCs, the study
design has improved with blinding, but the scientific
approach of the study is only modestly more robust. What
needs to be done? Should further studies with MSCs be
done on patients with MSA? This study is tantalizing but
clearly not definitive. Consequently, first the study should
be repeated in a multicenter double-blind study at some
point in time. Second, such a study should be done only
when a safer method of MSC delivery is available. Third,
the study should be carried out with both MSA-P and
MSA-C subjects. Fourth, as the benefits appear to be tran-
sient, the issue of mode of administration is important,
and future approaches will need to couple safer access with
a treatment paradigm that ensures sustained improvement.
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